PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092717
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092717
Transcutaneous Electrical Nerve Stimulation Market size was valued at US$ 534.12 Million in 2025, expanding at a CAGR of 9.5% from 2026 to 2033.
Transcutaneous Electrical Nerve Stimulation (TENS) is a non-invasive technique used in pain management, which involves the use of a battery-operated machine to generate low voltage electrical signals that pass-through electrodes attached on the skin. The electrical impulses stimulate the peripheral nerve endings and help in the reduction of both acute and chronic pain by inhibiting the transmission of pain signals to the brain and also by facilitating the production of pain-relieving chemicals like endorphins.
Transcutaneous Electrical Nerve Stimulation (TENS) is one of the common methods applied in the management of musculoskeletal pain, arthritis, back and neck pain, neuropathic pain, postoperative pain, labor pains, sports injuries, and other types of chronic pain. It can be performed in hospitals, physiotherapy clinics, pain management clinics or even at home with the help of portable and wearable TENS machines. Non-invasiveness, easy application, few side effects and lack of dependency on drugs make it a very attractive option.
Transcutaneous Electrical Nerve Stimulation Market- Market Dynamics
Rising prevalence of chronic pain conditions to propel market demand
The rise in the number of chronic pain conditions is the most important cause of the fast-growing TENS market. Arthritis, lower back pain, neuropathic pain, musculoskeletal diseases, fibromyalgia, and post-operative pain created a great need for safe and effective pain relief therapies. TENS units are used by physicians more and more frequently for multimodal treatment of pain and rehabilitation, as these devices provide effective pain reduction and have no danger of dependence and side effects linked to opioids. The growing use of home healthcare and wearables was an important factor that contributed to the popularity of TENS units.
The recent governmental statistics prove the tendency. According to the National Center for Health Statistics (NCHS) of the United States Centers for Disease Control and Prevention (CDC), 24.3% of US adults had chronic pain in 2023, or about 60 million people; of whom, 8.5% had high impact chronic pain, limiting their daily activities or work severely. The prevalence grew with age, reaching 36.0% in adults aged 65 years and older. In addition, according to the CDC's 2025 MMWR QuickStats, women still have higher prevalence rates of chronic pain compared to men (25.4% versus 23.2%).
The Global Transcutaneous Electrical Nerve Stimulation Market is segmented on the basis of Product Type, Application, End-Use, and Region.
The market is divided into two categories based on product type: Portable TENS and Table Top TENS. The Portable TENS dominates the market. Growth of the segment can be attributed to the rise in the number of portable devices and rise in the elderly population. The portable TENS device is ideal since it is compact and distinguishable. Thus, it can be carried around in pockets and on belts for instant pain relief in case it is required whether in hospital or outside. So, these are some of the reasons that are expected to drive the segment's growth during the forecast period.
The market is divided into two categories based on application: Chronic Pain and Acute Pain. The Acute Pain sector dominates the market and is likely to maintain its dominance during the forecast period. Subsegments for acute pain include sports injuries, postoperative pain, labor pain, and menstrual pain. Acute pain can be triggered by factors such as surgeries, trauma, sport-related injuries, and others. With increasing participation in sporting activities, there is an increase in risk of injuries. According to Stanford Medicine Children's Health, over 3.5 million injuries per year have been reported for children and adolescents aged 14 years and under who engage in sports in the U.S., in May 2024. Additionally, increasing instances of surgeries and increasing spending on health care will fuel the market growth during the forecast period. The use of opioids in the perioperative pain setting has been high. Nevertheless, negative side effects of opioids will lead to concerns over alternative treatments to manage pain using devices such as TENS.
Transcutaneous Electrical Nerve Stimulation Market- Geographical Insights
Nort America holds a prominent market share. One of the major factors driving growth includes the high prevalence rate of chronic pain. There are millions of patients in the United States and Canada suffering from conditions like osteoarthritis, lower back pain, neuropathic pain, musculoskeletal pain, and postoperative pain, thereby generating a constant need for TENS units in hospitals, physical rehabilitation facilities, physiotherapy clinics, and in-home use. Increasing worries over the addiction to opioids have prompted the healthcare organizations to add TENS therapy to pain management regimes.
US Transcutaneous Electrical Nerve Stimulation Market- Country Insights
The US capture a strong market share. The growth is owing to the increasing product approval. For instance, in July 2025, Bioventus Inc., which is Nasdaq listed under the ticker symbol BVS, an innovation leader in active healing solutions globally, has achieved a critical milestone with FDA 510(k) clearances for both TalisMann(TM) and StimTrial(TM), enhancing the Company's PNS product portfolio of innovative solutions in chronic pain. The FDA clearances for these two products have come as an achievement for the company, and it presents great potential growth in the PNS market as the Company continues with its efforts towards increasing its share in this rapidly-growing market, estimated to be growing over 20% every year and projected to surpass the $500 million mark by 2029. With FDA clearances for both TalisMann(TM) and StimTrial(TM), the Company has created a robust PNS portfolio, enabling doctors to have a wide range of options to evaluate and treat their patients with confidence using these new PNS technologies.
TENS market remains somewhat fragmented as there is competition among existing players which include medical device makers, rehabilitation equipment suppliers, as well as specialists in electrotherapy equipment. Market participants compete according to innovations, device mobility, availability of wireless technology, price, effectiveness of the treatment, distribution channels, and regulatory approval. In recent years companies have been increasingly involved in manufacturing TENS devices that are small, portable, and equipped with a capability of connecting to a smartphone.
Leading manufacturers spend considerable amounts of money on R&D in order to provide their customers with modern TENS systems including such features as Bluetooth compatibility, rechargeable batteries, customized treatment, digital interface, and mobile applications integration.
In July 2025, Neuros Medical, Inc., the maker of the Altius(R) Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment for chronic post-amputation pain, announced the closing of an oversubscribed $56 million Series D financing round. The funding will support U.S. commercialization and further development of its groundbreaking Altius(R) Direct Electrical Nerve Stimulation System.